Drug therapy of depression with anhedonia - to findings of the questionnaire survey of 1020 Russian psychiatrists

Background. Results of a previously conducted survey of practicing Russian psychiatrists revealed substantial variability in opinions regarding the pharmacotherapy of anhedonia. This article presents the results of a detailed, previously unpublished analysis of these opinions, reflecting practicing specialists’ current understanding of the pharmacotherapeutic options for anhedonia. Methods. Data from an online survey of 1020 practicing psychiatrists, collected between March and September 2025, were used. Open-ended responses to the questionnaire were thematically categorized, followed by statistical analysis of associations between the choice of psychopharmacotherapy and various sociodemographic and professional factors. Logistic regression was also performed to jointly assess the effects of sociodemographic and professional characteristics on the likelihood of mentioning venlafaxine as an effective medication for the treatment of anhedonia. Results. Although SSRIs were the most frequently mentioned antidepressant class considered effective for anhedonia by respondents (21,9% physicians), the most frequently mentioned individual antidepressants were venlafaxine (17,1% physicians), vortioxetine (13,7% physicians), agomelatine (12,5% physicians), and sertraline (8,6% physicians). Several characteristics were found to significantly increase the likelihood of mentioning venlafaxine: identifying melancholic depression (OR 2.609) as the type of depression most commonly associated with anhedonia, and working at a research center (OR 1.964). Working in a public healthcare institution significantly reduced the likelihood of selecting venlafaxine (OR 0.377). Discussion. The findings demonstrated that the overall pattern of opinions among practicing Russian psychiatrists regarding the pharmacotherapy of anhedonia is consistent with the established international evidence base. At the same time, these data may provide a basis for personalized educational programs for psychiatrists, as well as for targeted invitations to training programs that take the identified characteristics into account. Keywords: anhedonia, pharmacotherapy, antidepressants, venlafaxine.

Authors

Publication Details

Journal
Clinical review for general practice
Published
2026-11-16
DOI
https://doi.org/10.47407/kr2026.7.9.00938
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Drug therapy of depression with anhedonia - to findings of the questionnaire survey of 1020 Russian psychiatrists

Vladimir E. Medvedev, А.А. Кибитов, Olga Karpenko, Independent expert et al.
1 links
Clinical review for general practice
Treatment of Major Depression
article

Drug therapy of depression with anhedonia - to findings of the questionnaire survey of 1020 Russian psychiatrists

Vladimir E. Medvedev, А.А. Кибитов, Olga Karpenko, Independent expert, Alexander A Mukhin
article en

Abstract

Background. Results of a previously conducted survey of practicing Russian psychiatrists revealed substantial variability in opinions regarding the pharmacotherapy of anhedonia. This article presents the results of a detailed, previously unpublished analysis of these opinions, reflecting practicing specialists’ current understanding of the pharmacotherapeutic options for anhedonia. Methods. Data from an online survey of 1020 practicing psychiatrists, collected between March and September 2025, were used. Open-ended responses to the questionnaire were thematically categorized, followed by statistical analysis of associations between the choice of psychopharmacotherapy and various sociodemographic and professional factors. Logistic regression was also performed to jointly assess the effects of sociodemographic and professional characteristics on the likelihood of mentioning venlafaxine as an effective medication for the treatment of anhedonia. Results. Although SSRIs were the most frequently mentioned antidepressant class considered effective for anhedonia by respondents (21,9% physicians), the most frequently mentioned individual antidepressants were venlafaxine (17,1% physicians), vortioxetine (13,7% physicians), agomelatine (12,5% physicians), and sertraline (8,6% physicians). Several characteristics were found to significantly increase the likelihood of mentioning venlafaxine: identifying melancholic depression (OR 2.609) as the type of depression most commonly associated with anhedonia, and working at a research center (OR 1.964). Working in a public healthcare institution significantly reduced the likelihood of selecting venlafaxine (OR 0.377). Discussion. The findings demonstrated that the overall pattern of opinions among practicing Russian psychiatrists regarding the pharmacotherapy of anhedonia is consistent with the established international evidence base. At the same time, these data may provide a basis for personalized educational programs for psychiatrists, as well as for targeted invitations to training programs that take the identified characteristics into account. Keywords: anhedonia, pharmacotherapy, antidepressants, venlafaxine.

Clinical review for general practiceVol. 7(9)
Good health and well-being
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon